Nanoligent Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $14.1M

  • Investors
  • 12

Nanoligent General Information

Description

Developer of nanotechnology-based anti-cancer treatments intended to treat different types of metastatic cancer. The company utilizes protein engineering and nanobiotechnology to create self-assembling protein nanoparticles that selectively kill metastatic cells, enabling medical practitioners to improve patients' lives by designing medicines that target the cells affected by the disease through treatments more effective than classical drugs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Eureka Building,Avenue de Can Doménech s / n
  • UAB Campus, Bellaterra
  • 08193 Barcelona
  • Spain
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Corporate Office
  • Eureka Building,Avenue de Can Doménech s / n
  • UAB Campus, Bellaterra
  • 08193 Barcelona
  • Spain

Nanoligent Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nanoligent Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 06-Oct-2025 $14.1M Completed Pre-Clinical Trials
6. Grant 19-Jun-2025 Completed Pre-Clinical Trials
5. Accelerator/Incubator 21-Nov-2023 Completed Pre-Clinical Trials
4. Seed Round 27-Sep-2022 Completed Pre-Clinical Trials
3. Equity Crowdfunding 03-Feb-2022 Cancelled Pre-Clinical Trials
2. Seed Round 03-Feb-2022 $1.13M $1.13M Completed Pre-Clinical Trials
1. Grant 13-Dec-2018 $1.7K Completed Pre-Clinical Trials
To view Nanoligent’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Nanoligent Patents

Nanoligent Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-7810873-B2 Nidogen-based scaffold proteins and therapeutic nanocomplexes Active 26-Dec-2019
JP-2023509004-A Nidogen-based scaffold proteins and therapeutic nanocomposites Active 26-Dec-2019
JP-2026065032-A Nidogen-based scaffold proteins and therapeutic nanoconjugates Pending 26-Dec-2019
AU-2021204681-A1 Scaffold proteins and therapeutic nanoconjugates based on nidogen Pending 26-Dec-2019
CA-3166013-A1 Scaffold proteins and therapeutic nanoconjugates based on nidogen Pending 26-Dec-2019 C07K14/78
To view Nanoligent’s complete patent history, request access »

Nanoligent Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nanoligent Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Clave (Pamplona) Venture Capital Minority
INNVIERTE SICC Government Minority
Inveready Asset Management Venture Capital Minority
University of Alabama at Birmingham University
Archimedes Accelerator Accelerator/Incubator Minority
You’re viewing 5 of 12 investors. Get the full list »

Nanoligent FAQs

  • When was Nanoligent founded?

    Nanoligent was founded in 2017.

  • Where is Nanoligent headquartered?

    Nanoligent is headquartered in Barcelona, Spain.

  • What is the size of Nanoligent?

    Nanoligent has 9 total employees.

  • What industry is Nanoligent in?

    Nanoligent’s primary industry is Drug Delivery.

  • Is Nanoligent a private or public company?

    Nanoligent is a Private company.

  • What is Nanoligent’s current revenue?

    The current revenue for Nanoligent is .

  • How much funding has Nanoligent raised over time?

    Nanoligent has raised $18M.

  • Who are Nanoligent’s investors?

    Clave (Pamplona), INNVIERTE SICC, Inveready Asset Management, University of Alabama at Birmingham, and Archimedes Accelerator are 5 of 12 investors who have invested in Nanoligent.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process